FindMyKOL
Clinical trialNCT06612710RecruitingPhase 1Interventional

The Safety and Efficacy of NouvSoma001 in Ischemic Stroke

NCT06612710 is a phase 1 interventional trial sponsored by Wei Wang. As of 18 Nov 2026, it is recruiting participants. It studies A placebo of extracellular vesicles derived from human induced neural stem cell for intravenous injection and Extracellular vesicles derived from human induced neural stem cell for intravenous injection in Ischemic Stroke. The registry lists an enrollment of 69 participants at 1 site in 1 country. The registry lists a start date of 30 Nov 2025 and a primary completion date of 30 Dec 2026. One of its registered investigators has a FindMyKOL profile.

SponsorWei Wang →Enrollment69Ischemic Stroke
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT06612710
FieldValue
Registry IDNCT06612710
StatusRecruiting
PhasePhase 1
Study typeInterventional trial
Lead sponsorWei Wang
Enrollment69
Registered sites1
Countries1
ConditionsIschemic Stroke
DrugsA placebo of extracellular vesicles derived from human induced neural stem cell for intravenous injection and Extracellular vesicles derived from human induced neural stem cell for intravenous injection
Start30 Nov 2025
Primary completion30 Dec 2026
Study completion30 Nov 2027
Last update posted21 Jan 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a single-center, randomized, open-label, placebo-controlled, dose-escalation trial. The objective of this research is to evaluate the safety, tolerability, and preliminary efficacy of intravenous administration of human-induced neural stem cell-derived extracellular vesicles (NouvSoma001) in the treatment of ischemic stroke.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

China1 site, 1 recruiting
  • Tongji Hospital Affiliated To Tongji Medical College of Huazhong University Ofscience and Technology

    Wuhan, Hubei

    Chuan Qin, MDDaishi Tian, MDWei Wang, MD →
    Recruiting

Sites by country

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

A placebo of extracellular vesicles derived from human induced neural stem cell for intravenous injectionExtracellular vesicles derived from human induced neural stem cell for intravenous injection
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT06612710

Each answer restates registry values shown on this page.

What is NCT06612710?

NCT06612710 is a phase 1 interventional trial sponsored by Wei Wang. It studies A placebo of extracellular vesicles derived from human induced neural stem cell for intravenous injection and Extracellular vesicles derived from human induced neural stem cell for intravenous injection in Ischemic Stroke.

Is NCT06612710 recruiting?

As of 18 Nov 2026, it is recruiting participants. 1 of its 1 sites list their own status as recruiting.

Who leads NCT06612710?

The registry names Chuan Qin, MD (principal investigator, Tongji Hospital), Daishi Tian, MD (principal investigator, Tongji Hospital) and Wei Wang, MD (principal investigator, Tongji Hospital) as overall officials.

Where does NCT06612710 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: China.

Which drugs does NCT06612710 study?

The registered drug and biological interventions are A placebo of extracellular vesicles derived from human induced neural stem cell for intravenous injection and Extracellular vesicles derived from human induced neural stem cell for intravenous injection.

When is NCT06612710 expected to complete?

The registry lists a primary completion date of 30 Dec 2026 and a study completion date of 30 Nov 2027. The sponsor last updated the record on 21 Jan 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 18 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.